{
  "docId": "019de074-4761-73aa-b4e2-27087123bde2",
  "docSlug": "6f8a02d6c80778306574b231840d422a",
  "documentTitle": "argenx SE | Investor Presentation Deck | 23 slides",
  "authorId": "argenx-se",
  "authorName": "argenx",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-02-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 9,
  "pageCount": 23,
  "prevPage": 8,
  "nextPage": 10,
  "slideType": "key_takeaways",
  "function": "summarize",
  "density": "overcrowded",
  "nDataPoints": 4,
  "notes": "Includes a 3-step mechanism of action diagram.",
  "elementsJson": null,
  "metadataConfidence": 0.95,
  "imagePath": null,
  "slideHref": "/slides/019de074-4761-73aa-b4e2-27087123bde2/9",
  "deckHref": "/decks/019de074-4761-73aa-b4e2-27087123bde2",
  "deckJsonHref": "/decks/019de074-4761-73aa-b4e2-27087123bde2.json",
  "deckAnchorHref": "/decks/019de074-4761-73aa-b4e2-27087123bde2#slide-9",
  "components": [
    {
      "bbox": {
        "h": 0.1,
        "w": 0.96,
        "x": 0.02,
        "y": 0.83
      },
      "kind": "callout",
      "text": "Post-marketing data confirm positive benefit/risk profile as established in clinical trials",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0ad42402-b98e-42f9-80d4-8a022efba577",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.33,
        "x": 0.02,
        "y": 0.145
      },
      "kind": "callout",
      "text": "Scope of Safety Database",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8c0cab0b-8162-45d4-8c58-bccbb25c7cea",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.41,
        "x": 0.02,
        "y": 0.52
      },
      "kind": "callout",
      "text": "Molecular design yields unique interaction with FcRn and differentiated safety profile",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9ca57216-4c4c-432f-8532-130c14efcac6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.45,
        "x": 0.52,
        "y": 0.53
      },
      "kind": "diagram",
      "text": "1: Endogenous FcRn:IgG Interaction; 2: Fc-based antagonist retaining pH-dependent binding; 3: Anti-FcRn mAb blocking FcRn in a pH-independent fashion",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1d8b292a-0189-446d-8998-8126024b56ad",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.95,
        "x": 0.03,
        "y": 0.25
      },
      "kind": "list",
      "text": ">1,300 clinical study subjects; Cumulative exposure of >1,000 patient years; Different dosing regimens; TEAEs consistent across >4 indications; Low discontinuation rates",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d3ec0a38-a8cc-4971-9890-41ea3e617f5a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.4,
        "x": 0.02,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "1. Ulrichts P, et al. J Clin Invest. 2018;128(10):4372-4386. doi: 10.1172/JCI97911.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "dd58190e-1a1f-4797-aa51-e33b6af89d72",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.68,
        "x": 0.02,
        "y": 0.03
      },
      "kind": "title",
      "text": "2022: Broadened Scope of Efgartigimod Safety Database",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "80984ed7-ca6a-4134-9bf3-8ed00d0afe1a",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 10,
      "from": 8,
      "beatId": "01711734-e966-40d9-bdff-fd3a68b891cf",
      "arcName": "The Sparkline",
      "arcSlug": "sparkline",
      "beatName": "What Could Be",
      "beatSlug": "sparkline-what-could-be-2",
      "evidence": "Future potential and path to profitability",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}